Skip to content
FIND A HEALTH VALLEY ACTOR

Siegfried in Evionnaz: 150 years of pharmaceutical innovation

Siegfried - Marcel Signer

About fifty people from the Swiss Health Valley had the chance to visit the Siegfried production site in Evionnaz, during a BioAlps 4à6.     The story of Siegfried began in 1973 in the canton of Aargau. Back then, 12 people were dedicated to manufacturing raw materials for local pharmacies. Today, the group operates 11…

Read More

Lagosta partners with Merck for the distribution of Chitosan

Lagosta

LAGOSTA S.A. announces that it has entered into a collaboration with the global science and technology company Merck for the distribution of LAGOSTA’s unique chitosan.     Chitosan compound can be used by pharma, biotech and the biomedical industry for R&D use only, in drug delivery applications, 3D bioprinting and medical devices. Under the agreement,…

Read More

Lonza: 300 jobs in Visp for a new vaccine

Ibex™ Lonza facilit in Visp Switzerland

Lonza’s Visp site is preparing to manufacture components of a vaccine to protect against pneumococcus. Hundreds of jobs are at stake.     For Lonza, each day is different. After losing the contract to produce the active ingredients of the anti-Covid vaccine designed by Moderna, the company has just extended its collaboration with Californian company…

Read More

Hedera Dx Launches Blood Based Cancer Testing

Hedera Dx

Hedera Dx, a Vaud-based oncology company specializing in liquid biopsy testing, has unveiled a fully streamlined solution that allows hospitals to adopt liquid biopsy testing locally for their patients with minimal efforts. The solution is a combination of laboratory reagents and a software platform.     Liquid biopsies provide rapid, precise, non-invasive ways of assessing…

Read More

BioArk Monthey: a 3rd building dedicated to life sciences and biotechnologies

BioArk 3rd Building

BioArk is on a roll! The Monthey-based technology site, which is celebrating its 20th anniversary this year, inaugurated its third building on Friday 13 October 2023. And it is almost already full!     This new showcase, which houses companies specialising in life sciences and biotechnology, is already virtually full. It is proof that The…

Read More

Lonza further expands in Visps thanks to a new partnership

Lonza Visp

A new agreement with an undisclosed global biopharmaceutical partner will quadruple current dedicated bioconjugation capacity by adding two new production units for the commercial supply of Antibody-Drug Conjugates (ADC) at Lonza’s Ibex® Dedicate biopark in Visp (CH). 180 jobs will be created.     The announcement of Moderna’s departure does not hinder Lonza’s expansion! This…

Read More

Atinary Technologies raises CHF 4.6 Million

Atinary

The Biopôle-based start-up has developed a machine learning platform dedicated to materials discovery. The seed-round was round led by AgFunder and supported by Cherubic Ventures.   Atinary is dedicated to accelerating R&D and discovery across diverse industries, including pharmaceuticals, biotechnology, chemicals, energy, electronics, cosmetics, and food via its cutting-edge, no-code platform SDLabs. This investment will…

Read More

HAYA Therapeutics is Switzerland’s most promising startup

100 startups

The 13th edition of the TOP 100 Swiss Startup Award celebrated Switzerland’s best startups according to a 100-person strong jury: HAYA Therapeutics (1st), Planted Foods (2nd), and Yokoy Group (3rd) lead the ranking.   First place: HAYA Therapeutics | Epalinges (VDà The biotech startup HAYA Therapeutics develops precision drugs. The lead candidate for cardiac fibrosis…

Read More

A breakthrough in the US for Antion Biosciences SA

Antion Biosciences

Antion Biosciences SA (Antion), an innovative developer of cell and gene therapy technologies, announces the granting of a significant patent by the United States Patent and Trademark Office (USPTO).     The awarded patent, identified as US Patent No. US 11,649,455, further strengthens Antion’s position as a leading innovator in the cell and gene therapy…

Read More

CHF 40,000 For Diatheris

Diatheris

The Geneva-based biotech startup won Venture Kick’s second stage of financial and entrepreneurial support. The project aims to achieve optimal glycemic control while minimizing the risks of hypoglycemia and ketoacidosis   Type 1 diabetes (T1D) patients face significant challenges in achieving proper glycemic control without the risk of life-threatening hypoglycemia and ketoacidosis. Despite insulin therapy…

Read More